Browsing Tag
Thermo Fisher Scientific
37 posts
Thermo Fisher (NYSE: TMO) to offload Remel and Oxoid microbiology arm in $1bn Astorg deal
Thermo Fisher is selling a 95% recurring revenue microbiology business near its trading lows. The real question is what Marc Casper plans to do with the cash.
Stablepharma company profile: Business model, pipeline, and growth outlook (2026 edition)
Stablepharma is a UK biotech developing fridge-free vaccines and injectables via its StablevaX platform. Explore its Phase 1 pipeline, AFT Pharmaceuticals partnership, and 2026-2027 growth outlook.
Qiagen (NYSE: QGEN) at a crossroads ahead of new CEO and Q1 2026 results
Qiagen (NYSE: QGEN) retail investor roadmap: strategic review, CEO search, 2026 product pipeline and what the May earnings call means for shareholders.
The new engine of drug discovery? Inside Thermo Fisher Scientific’s cryo-EM hub in the Bay Area
Thermo Fisher Scientific opens a cryo-EM drug discovery center in South San Francisco to accelerate structural biology research. Discover why this matters for pharma.
Why Thermo Fisher Scientific (NASDAQ: TMO) is spending US$9.4bn on Clario to dominate clinical-trial analytics
Find out how Thermo Fisher’s US$9.4 billion acquisition of Clario is reshaping the clinical-trial services industry and what it means for investors.
Inside Thermo Fisher Scientific’s plan to harness OpenAI for faster, smarter biotech innovation
Find out how Thermo Fisher Scientific plans to use OpenAI’s generative AI to revolutionize research speed, accuracy, and discovery across life sciences.
Can Thermo Fisher’s new molecular test transform lung transplant care with faster rejection detection?
Discover how Thermo Fisher’s new AI-based MMDx Lung test improves early detection of lung transplant rejection and reshapes transplant diagnostics.
Vaxcyte’s $1bn Thermo Fisher deal: Can new U.S. vaccine capacity secure its PCV future?
Vaxcyte partners with Thermo Fisher in a $1B deal to build U.S. fill-finish vaccine capacity. Find out why this matters for its PCV pipeline and investors.
Thermo Fisher wins FDA approval for next-generation sequencing companion diagnostic tied to new HER2-mutant NSCLC therapy
Thermo Fisher wins FDA approval for its Oncomine Dx Target Test as a companion diagnostic for Boehringer Ingelheim’s new HER2-mutant NSCLC therapy.
Stablepharma’s fridge-free vaccine breakthrough: Dr Karen O’Hanlon explains the StablevaX journey
Find out how Stablepharma’s SPVX02 could redefine global vaccine logistics with fridge-free technology. Dr Karen O’Hanlon explains the science behind StablevaX™.